Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs

Advanced Drug Delivery Reviews

Volumn 64, Issue 6, 2012, Pages 480-495

  Kawakami, Kohsaku ^a  

^a NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

Author keywords

Amorphous; Bioavailability; Crystal form; Dissolution; Nanosuspension; Poorly soluble drug; Self emulsifying formulation; Solid dispersion; Supersaturation

Indexed keywords

BIOAVAILABILITY; CRYSTAL FORMS; NANO-SUSPENSIONS; POORLY SOLUBLE DRUGS; SELF-EMULSIFYING FORMULATION; SOLID DISPERSION;

AMORPHOUS MATERIALS; BIOCHEMISTRY; DISPERSIONS; DISSOLUTION; DRUG DOSAGE; SOLUBILITY; SUPERSATURATION;

EMULSIFICATION;

ALCOHOL; ALPHA TOCOTRIENOL; CARBAMAZEPINE; CASTOR OIL; CREMOPHOR; CYCLODEXTRIN; CYCLOSPORIN A; DANAZOL; DEOXYCHOLATE SODIUM; DIMETHYL SULFOXIDE; GELATIN; GRISEOFULVIN; HYDROXYPROPYLMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; IBUPROFEN; ITRACONAZOLE; MACROGOL 6000; MICONAZOLE; NIFEDIPINE; NITRENDIPINE; PACLITAXEL; POLOXAMER; POLYSORBATE 80; POVIDONE; PRANLUKAST; RITONAVIR; TACROLIMUS; TERT BUTYL ALCOHOL; TOCOFERSOLAN; UNINDEXED DRUG;

AREA UNDER THE CURVE; CAPSULE FILLING; CHEMICAL MODIFICATION; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; EMULSION; ENTHALPY; FREEZE DRYING; HUMAN; MATHEMATICAL ANALYSIS; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SUSPENSION; THERMODYNAMICS; X RAY POWDER DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; EMULSIONS; HUMANS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84859734219     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.10.009     Document Type: Review

References (163)

1. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23:3-25.
2. Hann M.M., Oprea T.I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 2004, 8:255-263.
3. Zhang M.Q., Wilkinson B. Drug discovery beyond the 'rule-of-five'. Curr. Opin. Biotechnol. 2007, 18:478-488.
4. Vistoli G., Pedretti A., Testaet B. Assessing drug-likeness-what are we missing?. Drug Discovery Today 2008, 13:285-294.
5. Brown D. Unfinished business: target-based drug discovery. Drug Discovery Today 2007, 12:1007-1012.
6. Kawakami K. Current status of amorphous formulation and other supersaturatable dosage forms as formulations for early clinical phases. J. Pharm. Sci. 2009, 98:2875-2885.
7. Brittain H.G. Polymorphism in pharmaceutical solids 1999, Marcel Dekker, New York.
8. Hilfiker R. Polymorphism in the pharmaceutical industry 2006, Wiley-VCH Verlag, Weinheim.
9. Rodríguez-Spong B., Price C.P., Jayasankar A., Matzger A.J., Rodríguez-Hornedo N. General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv. Drug Delivery Rev. 2004, 56:241-274.
10. Kawakami K. Reversibility of enantiotropically-related polymorphic transformations from a practical viewpoint: thermal analysis of kinetically reversible/irreversible polymorphic transformations. J. Pharm. Sci. 2007, 96:982-989.
11. Mishima O., Stanley H.E. The relationship between liquid, supercooled and glassy water. Nature 1998, 396:329-335.
12. Gu C.H., Grant D.J.W. Estimating the relative stability of polymorphs and hydrates from heats of solution and solubility data. J. Pharm. Sci. 2001, 90:1277-1287.
13. Lohani S., Grant D.J.W. Thermodynamics of polymorphs. Polymorphism in the Pharmaceutical Industry 2006, 21-42. Wiley-VCH Verlag, Weinheim. R. Hilfiker (Ed.).
14. Tian F., Zeitler J.A., Strachan C.J., Saville D.J., Gordon K.C., Rades T. Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy. J. Pharm. Biomed. Anal. 2006, 40:271-280.
15. Bugay D.E. Characterization of the solid-state: spectroscopic techniques. Adv. Drug Delivery Rev. 2001, 48:43-65.
16. Stephenson G.A., Forbes R.A., Reuzel-Edens S.M. Characterization of the solid state: quantitative issues. Adv. Drug Delivery Rev. 2001, 48:67-90.
17. Wartewig S., Neubert R.H.H. Pharmaceutical applications of Mid-IR and Raman spectroscopy. Adv. Drug Delivery Rev. 2005, 57:1144-1170.
18. Chalmers J.M., Dent G. Vibrational spectroscopic methods in pharmaceutical characterization. Polymorphism in the Pharmaceutical Industry 2006, 95-138. Wiley-VCH Verlag, Weinheim. R. Hilfiker (Ed.).
19. Otsuka M., Nishizawa J.I., Shibata J., Ito M. Quantitative evaluation of mefenamic acid polymorphs by teraherz-chemometrics. J. Pharm. Sci. 2010, 99:4048-4053.
20. Ikeda Y., Ishihara Y., Moriwaki T., Kato E., Terada K. A novel analytical method for pharmaceutical polymorphs by terahertz spectroscopy and the optimization for crystal form at the discovery stage. Chem. Pharm. Bull. 2010, 58:76-81.
21. Brittain H.G., Elder B.J., Isbester P.K., Salerno A.H. Solid-state fluorescence studies of some polymorphs of diflunisal. Pharm. Res. 2005, 22:999-1006.
22. Tishmack P.A., Bugay D.E., Byrn S.R. Solid-state nuclear magnetic resonance spectroscopy-pharmaceutical applications. J. Pharm. Sci. 2003, 92:441-474.
23. Lubach J.W., Munson E.J. Solid-state NMR spectroscopy. Polymorphism in the Pharmaceutical Industry 2006, 81-93. Wiley-VCH Verlag, Weinheim. R. Hilfiker (Ed.).
24. Craig D.Q.M. Characterization of polymorphic systems using thermal anlysis. Polymorphism in the Pharmaceutical Industry 2006, 43-79. Wiley-VCH Verlag, Weinheim. R. Hilfiker (Ed.).
25. Burger A., Ramberger R. On the polymorphism of pharmaceuticals and other molecular crystals. I. Theory of thermodynamic rules. Mikrochim. Acta 1979, 259-271. [Wien] II.
26. Burger A., Ramberger R. On the polymorphism of pharmaceuticals and other molecular crystals. II. Applicability of thermodynamic rules. Mikrochim. Acta 1979, 273-316. [Wien] II.
27. Kawakami K., Ida Y. Application of modulated-temperature DSC to the analysis of enantiotropically related polymorphic transitions. Thermochim. Acta 2005, 427:93-99.
28. Kawakami K., Asami Y., Takenoshita I. Calorimetric investigation of solvent-mediated transformation of sulfamerazine polymorphism. J. Pharm. Sci. 2010, 99:76-81.
29. Legas M., Lerk C.F. The polymorphism of sulfathiazole. Int. J. Pharm. 1981, 8:11-24.
30. Behme R.J., Brooke D. Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis. J. Pharm. Sci. 1991, 80(1991):986-990.
31. He X., Griesser U.J., Stowell J.G., Borchardt T.B., Byrn S.R. Conformational color polymorphism and control of crystallization of 5-methyl-2-[(4-methyl-2-nitrophenyl)amino]-3-thiophenecarbonitrile. J. Pharm. Sci. 2001, 90:371-388.
32. Yu L. Inferring thermodynamic stability relationship of polymorphs from melting data. J. Pharm. Sci. 1995, 84:966-974.
33. Gu C., Young V., Grant D.J.W. Polymorph screening: influence of solvents on the rate of solvent-mediated polymorphic transformation. J. Pharm. Sci. 2001, 90:1878-1890.
34. Miller J.M., Collman B.M., Greene L.R., Grant D.J.W., Blackburn A.C. Identifying the stable polymorph early in the drug discovery-development process. Pharm. Dev. Technol. 2005, 10:291-297.
35. Chemburkar S.R., Bauer J., Deming K., Spiwek H., Patel K., Morris J., Henry R., Spanton S., Dziki W., Porter W., Quick J., Bauer P., Donaubauer J., Narayanan B.A., Soldani M., Riley D., McFarland K. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org. Process. Res. Dev. 2000, 4:413-417.
36. Bauer J., Spanton S., Henry R., Quick J., Dziki W., Porter W., Morris J. Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. 2001, 18:859-866.
37. Morissette S.L., Soukasene S., Levinson D., Cima M.J., Almarsson Ö. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2180-2184.
38. Pudipeddi M., Serajuddin A.T.M. Trends in solubility of polymorphs. J. Pharm. Sci. 2005, 94:929-939.
39. Pudipeddi M., Serajuddin A.T.M., Grant D.J.W., Stahl P.H. Solubility and dissolution of weak acids, bases, and salts. Handbook of Pharmaceutical Salts: Properties, Selection, and Use 2002, 19-39. Verlag Helvetica Chimica Acta, Zurich. P.H. Stahl, C.G. Wermuth (Eds.).
40. Serajuddin A.T.M., Jarowski C.I. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical acids and their sodium salts II: salicylic acid, theophylline, and benzoic acid. J. Pharm. Sci. 1985, 74:148-154.
41. Serajuddin A.T.M. Salt formation to improve drug solubility. Adv. Drug Delivery Rev. 2007, 59:603-616.
42. Paulekuhn G.S., Dressman J.B., Saal C. Trends in active pharmaceutical ingredient salt selection based on analysis of the orange book database. J. Med. Chem. 2007, 50:6665-6672.
43. Benjamin E.J., Lin L.H. Preparation and in vitro evaluation of salts of an antihypertensive agent to obtain slow release. Drug Dev. Ind. Pharm. 1985, 11:771-790.
44. Shiraki K., Takata N., Takano R., Hayashi Y., Terada K. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm. Res. 2008, 25:2581-2592.
45. Good D.J., Rodríguez-Hornedo N. Solubility advantage of pharmaceutical cocrystals. Cryst. Growth Des. 2009, 9:2252-2264.
46. Bethune S.J., Huang N., Jayasankar A., Rodríguez-Hornedo N. Understanding and predicting the effect of cocrystal components and pH on cocrystal solubility. Cryst. Growth Des. 2009, 9:3976-3988.
47. Aakeröy C.B., Fasulo M.E., Desper J. Cocrystal or salt: does it really matter?. Mol. Pharm. 2007, 4:317-322.
48. Trask A.V., Sam Motherwell W.D., Jones W. Physical stability enhancement of theophylline via cocrystallization. Int. J. Pharm. 2006, 320:114-123.
49. Karki S., Friscic T., Fabian L., Laity P.R., Day G.M., Jones W. Improving mechanical propeties of crystalline solids by cocrystal formation: new compressible forms of paracetamol. Adv. Mater. 2009, 21:3905-3909.
50. Friscic T., Trask A.V., Jones W., Motherwell W.D.S. Screening for inclusion compounds and systematic construction of three-component solids by liquid-assisted grinding. Angew. Chem. Int. Ed. 2006, 45:7546-7550.
51. Lu E., Rodríguez-Hornedo N., Suryanarayanan R. A rapid thermal method for cocrystal screening. Cryst. Eng. Commun. 2008, 10:665-668.
52. Childs S.L., Rodríguez-Hornedo N., Reddy L.S., Jayasankar A., Maheshwari C., McCausland L., Shipplett R., Stahly B.C. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. Cryst. Eng. Commun. 2008, 10:856-864.
53. Li Z., Yang B.S., Jiang M., Eriksson M., Spinelli E., Yee N., Senanayake C. A practical solid form screen approach to identify a pharmaceutical glutaris acid cocrystal for development. Org. Process. Res. Dev. 2009, 13:1307-1314.
54. Kojima T., Tsutsumi S., Yamamoto K., Ikeda Y., Moriwaki T. High-throughput cocrystal slurry screening by use of in situ Raman microscopy and multi-well plate. Int. J. Pharm. 2010, 399:52-59.
55. Dhumal R.S., Kelly A.L., York P., Coates P.D., Paradkar A. Cocrystallization and simultaneous agglomeration using hot melt extrusion. Pharm. Res. 2010, 27:2725-2733.
56. Vishweshwar P., McMahon J.A., Bis J.A., Zaworotko M.J. Pharmaceutical co-crystals. J. Pharm. Sci. 2006, 95:499-516.
57. Porter W.W., Elie S.C., Matzger A.J. Polymorphism in carbamazepine cocrystals. Cryst. Growth Des. 2008, 8:14-16.
58. Allesø M., Chieng N., Rehder S., Rantanen J., Rhades T., Aaltonen J. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen-cimetidine mixtures prepared by mechanical activation. J. Control. Release 2009, 136:45-53.
59. Strickley R.G. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 2004, 21:201-230.
60. Kawakami K., Miyoshi K., Ida Y. Solubilization behavior of poorly soluble drugs with combined use of gelucire 44/14 and cosolvent. J. Pharm. Sci. 2004, 93:1471-1479.
61. Kawakami K., Oda N., Miyoshi K., Funaki T., Ida Y. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents. Eur. J. Pharm. Sci. 2006, 28:7-14.
62. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem. Pharm. Bull. 2004, 52:900-915.
63. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discovery 2004, 3:1023-1035.
64. Brewster M.E., Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Delivery Rev. 2007, 59:645-666.
65. 7M-β-CD on the solubilization of NSC-639829. Int. J. Pharm. 2004, 269:141-148.
66. Strickley R.G. Currently marketed oral lipid-based dosage forms: drug products and excipients. Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs 2007, 1-31. Informa Healthcare, New York. D.J. Hauss (Ed.).
67. Bowtle W.J. Materials, process, and manufacturing considerations for lipid-based hard-capsule formats. Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs 2007, 79-106. Informa Healthcare, New York. D.J. Hauss (Ed.).
68. Cole E.T., Cadé D., Benameur H. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. Adv. Drug Delivery Rev. 2008, 60:747-756.
69. Armstrong N.A., James K.C., Pugh W.K.L. Drug migration into soft gelatin capsule shells and its effect on in vitro availability. J. Pharm. Pharmacol. 1984, 36:361-365.
70. Lawrence M.J., Rees G.D. Microemulsion-based media as novel drug delivery systems. Adv. Drug Delivery Rev. 2000, 45:89-121.
71. Kawakami K., Yoshikawa T., Moroto Y., Kanaoka E., Takahashi K., Nishihara Y., Masuda K. Microemulsion formulation for enhanced absorption of poorly soluble drugs. I. Prescription design. J. Control. Release 2002, 81:65-74.
72. Rane S.S., Anderson B.D. What determines drug solubility in lipid vehicles: is it predictable?. Adv. Drug Delivery Rev. 2008, 60:638-656.
73. Fujioka Y., Metsugi Y., Hironaka T., Ochi M., Shundo A., Ogawara K., Higaki K., Kimura T. Improvement of oral absorption behavior of poorly water-soluble drug by using SMEDDS formulation: pharmacokinetic evaluation based on GITA model. Drug Metab. Rev. 2007, 39(Suppl. 1):91.
74. Yap S.P., Yuen K.H. Influence of lipolysis and droplet size on tocotrienol absorption from self-emulsifying formulations. Int. J. Pharm. 2004, 281:67-78.
75. Kovarik J.M., Mueller E.A., van Bree J.B., Tetzloff W., Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 1994, 83:444-446.
76. Kawakami K., Yoshikawa T., Hayashi T., Nishihara Y., Masuda K. Microemulsion formulation for enhanced absorption of poorly soluble drugs. II. In vivo study. J. Control. Release 2002, 81:75-82.
77. Porter C.J.H., Kaukonen A.M., Boyd B.J., Edwards G.A., Charman W.N. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm. Res. 2004, 21:1405-1412.
78. Porter C.J.H., Pouton C.W., Cuine J.F., Charman W.N. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Delivery Rev. 2008, 60:673-691.
79. Kawakami K., Yoshikawa T. Recent development in microemulsions-based formulations. Curr. Top. Colloid Interface Sci. 2001, 4:153-166.
80. Grove M., Müllertz A., Nielsen J.L., Pedersen G.M. Bioavailability of secalcitol II: development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Eur. J. Pharm. Sci. 2006, 28:233-242.
81. Cuiné J.F., McEvoy C.L., Charman W.N., Pouton C.W., Edwards G.A., Benameur H., Porter C.J.H. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J. Pharm. Sci. 2008, 97:993-1010.
82. González R.C.B., Huwyler J., Walter I., Mountfield R., Bittner B. Improved oral bioavailability of cyclosporin a in male wistar rats. Comparison of a solutol HS 15 containing self-dispersing formulation and a microsuspension. Int. J. Pharm. 2002, 245:143-151.
83. Wacher V.J., Wong S., Wong H.T. Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-α-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. J. Pharm. Sci. 2002, 91:77-90.
84. Yang S., Gursoy R.N., Lambert G., Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concominant use of P-glycoprotein inhibitors. Pharm. Res. 2004, 21:261-270.
85. Constantinides P.P., Wasan K.M. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro / in vivo case studies. J. Pharm. Sci. 2007, 96:235-248.
86. O'Driscoll C.M., Griffin B.T. Biopharmaceutical challenges associated with drugs with low aqueous solubility-the potential impact of lipid-based formulations. Adv. Drug Delivery Rev. 2008, 60:617-624.
87. Trevaskis N.L., Charman W.N., Porter C.J.H. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv. Drug Delivery Rev. 2008, 60:702-716.
88. Gao P., Morozowich W. Design and development of supersaturatable delf-emulsifying drug delivery systems for enhancing the gastrointestinal absorption of poorly soluble drugs. Oral Lipid-based Formulations: Enhancing the Bioavailability of Poorly Water-soluble Drugs 2007, 303-327. Informa Healthcare, New York. D.J. Hauss (Ed.).
89. Gao P., Rush B.D., Pfund W.P., Huang T., Bauer J.M., Morozowich W., Kuo M.S., Hageman M.J. Development of a supersaturatable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 2003, 92:2386-2398.
90. Gao P., Akrami A., Alvarez F., Hu J., Li L., Ma C., Surapaneni S. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. J. Pharm. Sci. 2009, 98:516-528.
91. Kawakami K. Isothermal crystallization of Imwitor 742 from supercooled liquid state. Pharm. Res. 2007, 24:738-747.
92. Guzmán H.R., Tawa M., Zhang Z., Ratanabanangkoon P., Shaw P., Gardner C.R., Chen H., Monreau J., Almarsson O., Remenar J.F. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J. Pharm. Sci. 2007, 96:2686-2702.
93. Brouwers J., Brewster M.E., Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?. J. Pharm. Sci. 2009, 98:2549-2572.
94. Zipp G.L., Rodríguez-Hornedo N. Phenytoin crystal growth rates in the presence of phosphate and chloride ions. J. Cryst. Growth 1992, 123:247-254.
95. Mohan R., Myerson A.S. Growth kinetics: a thermodynamic approach. Chem. Eng. Sci. 2002, 57:4277-4285.
96. Kawakami K., Miyoshi K., Ida Y. Impact of the amount of excess solids on apparent solubility. Pharm. Res. 2005, 22:1537-1543.
97. Murdande S.B., Pikal M.J., Shanker R.M., Bogner R.H. Solubility advantage of amorphous pharmaceuticals: I. Thermodynamic analysis. J. Pharm. Sci. 2010, 99:1254-1264.
98. Alonzo D.E., Zhang G.G.Z., Zhou D., Gao Y., Taylor L.S. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm. Res. 2010, 27:608-618.
99. Angell C.A., Ngai K.L., McKenna G.B., McMillan P.F., Martin S.W. Relaxation in glassforming liquids and amorphous solids. J. Appl. Phys. 2000, 88:3113-3157.
100. Kawakami K., Pikal M.J. Calorimetric investigation of the structural relaxation of amorphous materials: evaluating validity of the methodologies. J. Pharm. Sci. 2005, 94:948-965.
101. Shamblin S.L., Hancock B.C., Pikal M.J. Coupling between chemical reactivity and structural relaxation in pharmaceutical glasses. Pharm. Res. 2006, 23:2254-2268.
102. Yoshioka S., Aso Y. Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals. J. Pharm. Sci. 2007, 96:960-981.
103. Luthra S.A., Hodge I.M., Utz M., Pikal M.J. Correlation of annealing with chemical stability in lyophilized pharmaceutical glasses. J. Pharm. Sci. 2008, 97:5240-5251.
104. Sjökvist E., Nyström C., Aldén M., Caram-Lelham N. Physicochemical aspects of drug release. XIV. The effects of some ionic and non-ionic surfactants on properties of a sparingly soluble drug in solid dispersions. Int. J. Pharm. 1992, 79:123-133.
105. Crowley K.J., Zografi G. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability. J. Pharm. Sci. 2002, 91:492-507.
106. Sollohub K., Cal K. Spray drying technique: II. Current applications in pharmaceutical technology. J. Pharm. Sci. 2010, 99:587-597.
107. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm. 2002, 54:107-117.
108. Teagarden D.L., Baker D.S. Practical aspects of lyophilization using non-aqueous co-solvent systems. Eur. J. Pharm. Sci. 2002, 15:115-133.
109. Den Brok M.W.J., Nuijen B., Lutz C., Opitz H.G., Beijnen J.H. Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent imexon using dimethyl sulfoxide as solubilising and stabilising agent. J. Pharm. Sci. 2005, 94:1101-1114.
110. Yasuji T., Takeuchi H., Kawashima Y. Particle design of poorly water-soluble substances using supercritical fluid technologies. Adv. Drug Delivery Rev. 2008, 60:388-398.
111. Pasquali I., Bettini R., Giordano F. Supercritical fluid technologies: an innovative approasch for manipulating the solid-state of pharmaceuticals. Adv. Drug Delivery Rev. 2008, 60:399-410.
112. Chakraborty S., Liao I.C., Adler A., Leong K.W. Electrohydrodynamics: a facile technique to fabricate drug delivery systems. Adv. Drug Delivery Rev. 2009, 61:1043-1054.
113. Zhang S., Kawakami K. One-step preparation of chitosan solid nanoparticles by electrospray deposition. Int. J. Pharm. 2010, 397:211-217.
114. Zhang S., Kawakami K., Yamamoto M., Masaoka Y., Kataoka M., Yamashita S., Sakuma S. Coaxial electrospray formulations for improving oral absorption of a poorly water-soluble drug. Mol. Pharm. 2011, 8:807-813.
115. Rumondor A.C.F., Marsac R.J., Stanford L.A., Taylor L.S. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the persence of moisture. Mol. Pharm. 2009, 6:1492-1505.
116. Marsac R.J., Rumondor A.C.F., Nivens D.E., Kestur U.S., Stanciu L., Taylor L.S. Effect of temperature and moisture on the miscibility of amorphous dispersions of felodipine and poly(vinyl pyrrolidone). J. Pharm. Sci. 2010, 99:169-185.
117. Hancock B.C., Zografi G. The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm. Res. 1994, 11:471-477.
118. Crowley K.J., Zografi G. Water vapor absorption into amorphous hydrophobic drug/poly(vinylpyrrolidone) dispersions. J. Pharm. Sci. 2002, 90:2150-2165.
119. Dong Z., Chatterji A., Sandhu H., Choi D.S., Chokshi H., Shah N. Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation. Int. J. Pharm. 2008, 355:141-149.
120. Janssens S., De Zeure A., Paudel A., Van Humbeeck J., Rombaut P., Van den Mooter G. Influence of preparation methods on solid state supersaturation of amorphousb solid dispersions: a case study with itraconazole and eudragit E100. Pharm. Res. 2010, 27:775-785.
121. Guns S., Dereymaker A., Kayaert P., Mathot V., Martens J.A., Van den Mooter G. Comparison between hot-melt extrusion and spray-drying for manifacturing solid dispersions of the graft copolymer of ethylene glycol and vinylalcohol. Pharm. Res. 2011, 28:673-682.
122. Bank M., Leffingwell J., Thies C. The influence of solvent upon the compatibility of polystyrene and ploy(vinyl methyl ether). Macromolecules 1971, 4:43-46.
123. Baird J.A., Van Eerdenbrugh B., Taylor L.S. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J. Pharm. Sci. 2010, 99:3787-3806.
124. Van Eerdenbrugh B., Baird J.A., Taylor L.S. Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation-classification and comparison with crystallization tendency from undercooled melts. J. Pharm. Sci. 2010, 99:3826-3838.
125. Gupta M.K., Vanwert A., Bogner R.H. Formation of physically stable amorphous drugs by milling with neusilin. J. Pharm. Sci. 2003, 92:536-551.
126. Wang F., Hui H., Barnes T.J., Barnett C., Prestidge C.A. Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs. Mol. Pharm. 2010, 227-236.
127. Lauer M.E., Grassmann O., Siam M., Tardio J., Jacob L., Page S., Kindt J.H., Engel A., Alsenz J. Atomic force microscopy-based screening of drug-excipient miscibility and stability of solid dispersions. Pharm. Res. 2011, 28:572-584.
128. Vandecruys R., Peeters J., Verreck G., Brewster M.E. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int. J. Pharm. 2007, 342:168-175.
129. Shanbhag A., Rabel S., Nauka E., Casadevall G., Shivanand P., Eichenbaum G., Mansky P. Method for screening of solid dispersion formulations of low-solubility compounds-miniaturization and automation of solvent casting and dissolution testing. Int. J. Pharm. 2008, 351:209-218.
130. 13C solid state NMR. Polymer 2002, 43:1357-1364.
131. Asano A., Takegoshi K., Hikichi K. Solid-state NMR study of miscibility and phase-separation of polymer blend: polycarbonate/poly(methyl methacrylate). Polym. J. 1992, 24:555-562.
132. Verreck G., Vandecruys R., De Conde V., Baert L., Peeters J., Brewster M.E. The use of three different solid dispersion formulations-melt extrusion, film-coated beads, and a glass thermoplastic system-to improve the bioavailability of a novel microsomal triglyceride transfer protein inhibitor. J. Pharm. Sci. 2004, 93:1217-1228.
133. Law D., Schmitt E.A., Marsh K.C., Everitt E.A., Wang W., Fort J.J., Krill S.L., Qiu Y. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations. J. Pharm. Sci. 2004, 93:563-570.
134. Bhugra C., Pikal M.J. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J. Pharm. Sci. 2008, 97:1329-1349.
135. Caron V., Bhugra C., Pikal M.J. Prediction of onset of crystallization in amorphous pharmaceutical systems: phenobarbital, nifedipine/PVP, and phenobarbital/PVP. J. Pharm. Sci. 2010, 99:3887-3900.
136. Miller D.A., McConville J.T., Yang W., Williams R.O., McGinity J.W. Hot-melt extrusion for enhanced delivery of drug particles. J. Pharm. Sci. 2007, 96:361-376.
137. Newa M., Bhandari K.H., Li D.X., Kwon T.H., Kim J.A., Yoo B.K., Woo J.S., Lyoo W.S., Yong C.S., Choi H.G. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. Int. J. Pharm. 2007, 343:228-237.
138. Chono S., Takeda E., Seki T., Morimoto K. Enhancement of the dissolution rate and gastrointestinal absorption of pranlukast as a model poorly water-soluble drug by grinding with gelatin. Int. J. Pharm. 2008, 347:71-78.
139. Zerrouk N., Chemtob C., Arnaud P., Toscani S., Dugue J. In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions. Int. J. Pharm. 2001, 225:49-62.
140. Sugimoto I., Kuchiki A., Nakagawa H., Tohgo K., Kondo S., Iwane I., Takahashi K. Dissolution and absorption of nifedipine from nifedipine-polyvinylpyrrolidone coprecipitate. Drug Dev. Ind. Pharm. 1980, 6:137-160.
141. Kushida I., Ichikawa M., Asakawa N. Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble Dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J. Pharm. Sci. 2002, 91:258-266.
142. Friesen D.T., Shanker R., Crew M., Smithey D.T., Curatolo W.J., Nightingale J.A.S. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol. Pharm. 2008, 5:1003-1019.
143. Yamashita K., Nakate T., Okimoto K., Ohike A., Tokunaga Y., Ibuki R., Higaki K., Kimura T. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm. 2003, 267(2003):79-91.
144. Kohri N., Yamayoshi Y., Xin H., Iseki K., Sato N., Todo S., Miyazaki K. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J. Pharm. Pharmacol. 1999, 51:159-164.
145. Sekiguchi K., Obi N. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull. 1961, 9:866-872.
146. Byrn S.R., Xu W., Newman A.W. Chemical reactivity in solid-state pharmaceuticals: formulation implications. Adv. Drug Delivery Rev. 2001, 48:115-136.
147. Ford J.J. The current status of solid dispersions. Pharm. Acta Helv. 1986, 61:69-88.
148. Serajuddin A.T.M. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88:1058-1066.
149. Verma S., Burgess D. Solid nanosuspensions: the emerging technology and pharmaceutical applications as nanomedicine. Pharmaceutical Suspensions: From Formulation Development to Manufacturing 2010, 285-318. Springer, New York. A.K. Kulshreshtha, O.N. Singh, G.M. Wall (Eds.).
150. Kesisoglou F., Panmai S., Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Delivery Rev. 2007, 59:631-644.
151. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 1996, 13:1838-1845.
152. Lai S.K., O'Hanlon D.E., Harrold S., Man S.T., Wang Y.Y., Cone R., Hanes J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1482-1487.
153. Merisko-Liversidge E., Liversidge G.G., Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003, 18:113-120.
154. Van Eedenbrugh B., Van den Mooter G., Augustijins P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int. J. Pharm. 2008, 364:64-75.
155. Pongpeerapat A., Wanawongthai C., Tozuka Y., Moribe K., Yamamoto K. Formation mechanism of colloidal nanoparticles obtained from probucol/PVP/SDS ternary ground mixture. Int. J. Pharm. 2008, 352:309-316.
156. Wanawongthai C., Pongpeerapat A., Higashi K., Tozuka Y., Moribe K., Yamamoto K. Nanoparticle formation from probucol/PVP/sodium alkyl sulfate co-ground mixture. Int. J. Pharm. 2009, 376:169-175.
157. Rasenack N., Hartenhauer H., Müller B.W. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int. J. Pharm. 2003, 254:137-145.
158. De Waard H., Hinrichs W.L.J., Frijlink H.W. A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying. J. Control. Release 2008, 128:179-183.
159. Qian F., Tao J., Desikan S., Hussain M., Smith R.L. Mechanistic investigation of pluronic based nano-crystalline drug-polymer solid dispersions. Pharm. Res. 2007, 24:1551-1560.
160. 2 system for nanoparticle preparation of indomethacin. Int. J. Pharm. 2010, 386:243-248.
161. Abdelwahed W., Degobert G., Stainmesse S., Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv. Drug Delivery Rev. 2006, 58:1688-1713.
162. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 2006, 111:56-64.
163. Wu Y., Loper A., Landis E., Hettrick L., Novak L., Lynn K., Chen C., Thompson K., Higgins R., Batra U., Shelukar S., Kwei G., Storey D. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 2004, 285:135-146.